Effects of a Fixed-Dose Co-Formulation of Daclatasvir, Asunaprevir, and Beclabuvir on the Pharmacokinetics of a Cocktail of Cytochrome P450 and Drug Transporter Substrates in Healthy Subjects

Tushar Garimella,Xiaolu Tao,Karen Sims,Yi-Ting Chang,Jignasa Rana,Elsa Myers,Megan Wind-Rotolo,Rahul Bhatnagar,Timothy Eley,Frank LaCreta,Malaz AbuTarif

Effects of a Fixed-Dose Co-Formulation of Daclatasvir, Asunaprevir, and Beclabuvir on the Pharmacokinetics of a Cocktail of Cytochrome P450 and Drug Transporter Substrates in Healthy Subjects

2018

Tushar Garimella
Xiaolu Tao
Karen Sims
Yi-Ting Chang
Jignasa Rana
Elsa Myers
Megan Wind-Rotolo
Rahul Bhatnagar
Timothy Eley
Frank LaCreta
Malaz AbuTarif

Background A fixed-dose combination of daclatasvir (DCV; hepatitis C virus NS5A inhibitor), asunaprevir (ASV; non-structural protein 3 inhibitor), and beclabuvir (BCV; non-structural protein 5B inhibitor) is approved in Japan for hepatitis C virus genotype 1.

Keywords:

Diabetes mellitus
Drug
Pharmacology
Cytochrome P450
Medicine
Asunaprevir
Beclabuvir
Transporter
Daclatasvir
Pharmacokinetics
healthy subjects
drug transporter
fixed dose

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations